Preliminary Late-Stage Study Boosts Eli Lilly Stock

Eli Lilly And Co (NYSE:LLY) announced today preliminary results from a late-stage study indicated the main ingredients Zepbound and Mounjaro of weight-loss drug tirzepatide reduced the risk of progression to type 2 diabetes by 94%. Additionally, patients saw weight reduction of about 15% to 23%, depending on drug dosage.In response, LLY is up 2.4% to trade at $943.22 at last check. The shares are bouncing off a pullback from a July 15, record high of $966.10 to the $740 region, with a newfound floor at the ...